| << Back |
Acceleron Appoints Jay T. Backstrom, M.D., M.P.H., to Newly Created Role as Head of Research and Development
“During his time at Celgene, I personally found Jay to be an outstanding partner and collaborator, and I couldn’t be more thrilled to be working alongside him,” said
Dr. Backstrom brings to Acceleron nearly three decades of global clinical and regulatory experience in preparing and executing development strategies leading to regulatory approvals across a broad range of therapeutic areas, including hematologic, oncologic, immunologic, cardiovascular, and pulmonary diseases.
Dr. Backstrom joined Celgene in 2008 as Vice President, Clinical R&D with a focus in hematology/oncology, later advancing to the position of CMO and Head of Regulatory Affairs. Prior to Celgene, he served as Vice President, Global Medical Affairs and Safety at Pharmion. Dr. Backstrom began his career in industry in 1990 at Marion Merrell Dow and continued as part of its successor companies including Hoechst Marion Roussel, where he held positions in Clinical Research and Global Drug Surveillance and Pharmacoepidemiology. He also spent nearly three years at Quintiles in Medical and Scientific Services, including Therapeutic Head, Cardiovascular, Respiratory and Critical Care where he oversaw extensive clinical work across a variety of cardiovascular and pulmonary diseases.
Dr. Backstrom served as staff physician and Medical Director of the
“It’s a privilege to be joining a company I know so well and have long admired,” said Dr. Backstrom. “I’ve witnessed first-hand the impact Acceleron’s expertise in TGF-beta superfamily biology could have in the hematology space, and so I now look forward to helping the Company further develop and fully realize the potential of its pipeline in additional therapeutic areas.”
About Acceleron
Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.
Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner,
For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191209005252/en/
Source:
Acceleron Pharma Inc.
Investors:
Todd James, IRC, (617) 649-9393
Vice President, Investor Relations and Corporate Communications
Ed Joyce, (617) 649-9242
Director, Investor Relations
Media:
Matt Fearer, (617) 301-9557
Director, Corporate Communications